Meta (META) stock is dipping on reports that the company is restructuring its artificial intelligence (AI) unit for the ...

Shares of Novo Nordisk (NYSE: NVO), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped ...

Insider trading activity often serves as a window into how company executives view their own businesses. When insiders buy, ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.